Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients
Effect of Neuromuscular Reversal Agents on Time for Neurological Assessment After Endotracheal Intubation in Critically Ill Patients
Seoul National University Hospital
30 participants
Jan 11, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to compare the effect of use of reversal agents for neuromuscular blockade in critically ill patients on time for neurological assessment after endotracheal intubation The main questions it aims to answer are: * The use of reversal agents for neuromuscular blockade after endotracheal intubation may reduce the time for neurological assessment. * The types of reversal agents for neuromuscular blockade may affect the time for neurological assessment. Participants will receive different reversal agents or no medications based on the assigned groups. Thirty minutes after intubation using rocuronium, medication is administered, and the time of initial confirmation of eye opening and movement is recorded. Researchers will compare 3 groups (sugammadex, neostigmine and control(no medication) to see the difference of time for neurological assessment after endotracheal intubation.
Eligibility
Inclusion Criteria1
- Adult patients 19 years of age or older who were intubated after admission to the intensive care unit.
Exclusion Criteria5
- Patients younger than 19 years of age
- Patients who are not neurologically evaluable or have concomitant neurologic dysfunction
- Patients with neuromuscular disorder
- Patients with a history of drug allergic reactions to sugammadex or neostigmine
- Patients taking or planning to take toremifene, fusidic acid, or hormonal contraceptives
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous administration of sugammadex 2mg/kg.
Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05993390